Joaquim Ferreira
Joaquim Ferreira
Faculdade de Medicina, Universidade de Lisboa
Verified email at - Homepage
Cited by
Cited by
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
DG Healy, M Falchi, SS O'Sullivan, V Bonifati, A Durr, S Bressman, ...
The Lancet Neurology 7 (7), 583-590, 2008
How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor
ED Louis, JJ Ferreira
Movement Disorders 25 (5), 534-541, 2010
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
A Di Fonzo, CF Rohé, J Ferreira, HF Chien, L Vacca, F Stocchi, L Guedes, ...
The Lancet 365 (9457), 412-415, 2005
EFNS/MDS‐ES recommendations for the diagnosis of P arkinson's disease
A Berardelli, GK Wenning, A Antonini, D Berg, BR Bloem, V Bonifati, ...
European journal of neurology 20 (1), 16-34, 2013
Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of P arkinson's disease
JJ Ferreira, R Katzenschlager, BR Bloem, U Bonuccelli, D Burn, ...
European journal of neurology 20 (1), 5-15, 2013
Corticosteroids for Bell's palsy (idiopathic facial paralysis)
RA Salinas, G Alvarez, F Daly, J Ferreira
Cochrane database of systematic reviews, 2010
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
A Di Fonzo, HF Chien, M Socal, S Giraudo, C Tassorelli, G Iliceto, ...
Neurology 68 (19), 1557-1562, 2007
Limitations of current Parkinson's disease therapy
O Rascol, P Payoux, F Ory, JJ Ferreira, C Brefel‐Courbon, JL Montastruc
Annals of Neurology: Official Journal of the American Neurological …, 2003
Quantitative wearable sensors for objective assessment of Parkinson's disease
W Maetzler, J Domingos, K Srulijes, JJ Ferreira, BR Bloem
Movement Disorders 28 (12), 1628-1637, 2013
Dopamine agonist therapy in early Parkinson's disease
R Stowe, N Ives, CE Clarke, J Ferreira, RJ Hawker, L Shah, K Wheatley, ...
Cochrane Database of Systematic Reviews, 2008
DYSBOT: a single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin …
C Sampaio, JJ Ferreira, F Simões, MJ Rosas, M Magalhães, AP Correia, ...
Movement disorders 12 (6), 1013-1018, 1997
Sleep attacks and Parkinson's disease treatment
JJ Ferreira, M Galitzky, JL Montastruc, O Rascol
The Lancet 355 (9212), 1333-1334, 2000
Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease
M Martins, A Rosa, LC Guedes, BV Fonseca, K Gotovac, S Violante, ...
PloS one 6 (10), e25443, 2011
Botulinum toxin type A therapy for blepharospasm
J Costa, CC Espírito‐Santo, AA Borges, J Ferreira, MM Coelho, P Moore, ...
Cochrane Database of Systematic Reviews, 2004
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations
B Högl, I Arnulf, C Comella, J Ferreira, A Iranzo, B Tilley, C Trenkwalder, ...
Movement Disorders 25 (16), 2704-2716, 2010
Therapeutic interventions for symptomatic treatment in Huntington's disease
T Mestre, J Ferreira, MM Coelho, M Rosa, C Sampaio
Cochrane Database of Systematic Reviews, 2009
The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor
S Goldwurm, A Di Fonzo, EJ Simons, CF Rohe, M Zini, M Canesi, S Tesei, ...
Journal of medical genetics 42 (11), e65-e65, 2005
Botulinum toxin type A therapy for cervical dystonia
J Costa, CC Espírito‐Santo, AA Borges, J Ferreira, MM Coelho, P Moore, ...
Cochrane Database of Systematic Reviews, 2005
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
A Di Fonzo, C Tassorelli, M De Mari, HF Chien, J Ferreira, CF Rohé, ...
European journal of human genetics 14 (3), 322-331, 2006
Late-stage Parkinson disease
M Coelho, JJ Ferreira
Nature Reviews Neurology 8 (8), 435-442, 2012
The system can't perform the operation now. Try again later.
Articles 1–20